文献速递中毒与环境急症消化、代谢与肾脏急症

血清水杨酸盐浓度不可测后的水杨酸盐毒性:一项回顾性队列研究

Salicylate toxicity after undetectable serum salicylate concentration: a retrospective cohort study.
PubMed 文献 · Clin Toxicol (Phila) · 2018-10-11
一句话结论约3.5%的水杨酸盐中毒患者早期血清水杨酸盐浓度不可测,首次检测更早、达峰时间更长,需系列监测。

该单中心回顾性队列研究分析了2002至2016年间313例接受碳酸氢钠治疗且血清水杨酸盐浓度([ASA])>30 mg/dL的中毒病例,其中11例(3.5%)初始[ASA]不可测,302例(96.5%)可测。不可测组首次[ASA]检测时间更早(89 vs. 137分钟,p=0.011),但达峰时间更长(640 vs. 321分钟,p<.001)。两组峰值[ASA]和报告摄入剂量无显著差异,合并延缓胃排空药物比例及血液透析比例亦无显著差异。作者认为[ASA]可能在过量早期不可测,需进一步探索系列[ASA]检测在评估中的必要性。

要点

  • 在313例[ASA]>30 mg/dL的水杨酸盐中毒患者中,11例(3.5%)初始[ASA]不可测,提示早期单次检测阴性不能排除中毒。
  • 不可测组首次[ASA]检测时间更早(89 vs. 137分钟,p=0.011),达峰时间更长(640 vs. 321分钟,p<.001)。
  • 两组峰值[ASA](45 vs. 50 mg/dL,p=NS)和报告摄入剂量(19.7 g vs. 32.9 g,p=NS)无显著差异。
  • 合并延缓胃排空药物比例(18% [2/11] vs. 25% [76/302],p=NS)及血液透析比例(9% [1/11] vs. 5.6% [17/302],p=NS)无显著差异。
  • 整个队列仅1例死亡,发生于初始[ASA]可测的患者。

适用人群与场景

  • 单中心区域中毒中心2002至2016年记录的、接受碳酸氢钠治疗且[ASA]>30 mg/dL的水杨酸盐中毒病例。
  • 排除初始[ASA]在就诊后>4小时才获得的病例。

诊断标准与关键阈值

  • 水杨酸盐中毒:接受碳酸氢钠治疗且[ASA]>30 mg/dL。
  • 初始[ASA]不可测定义为血清水杨酸盐浓度检测不到。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究,共纳入313例,其中初始[ASA]不可测11例(3.5%),可测302例(96.5%)。
  • 不可测组首次[ASA]检测时间更早(89 vs. 137分钟,p=0.011),达峰时间更长(640 vs. 321分钟,p<.001)。
  • 摄入至不可测[ASA]的最长间隔为225分钟。
  • 两组峰值[ASA](45 vs. 50 mg/dL,p=NS)和报告平均摄入剂量(19.7 g vs. 32.9 g,p=NS)相似。
  • 合并延缓胃排空药物比例:不可测组18%(2/11) vs. 可测组25%(76/302),p=NS(卡方检验)。
  • 血液透析比例:不可测组9%(1/11) vs. 可测组5.6%(17/302),p=NS(卡方检验)。
  • 整个队列仅1例死亡,发生于初始[ASA]可测的患者。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:初始[ASA]不可测的患者数量少;使用单中心中毒中心数据;合并摄入物和阿司匹林剂型的部分数据缺失。

对床旁实践的改变

  • 作者认为,[ASA]在过量后早期可能不可测,应进一步探索系列[ASA]检测在水杨酸盐摄入评估中的必要性。
  • 作者指出,需要额外研究以确定任何致病因素和[ASA]测量的最佳时机。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Salicylates are usually rapidly absorbed and quickly measurable in serum. An undetectable serum salicylate concentration ([ASA]) may occur early after ingestion and may be interpreted as evidence of non-exposure and not repeated. Although cases of delayed salicylate detection are reported rarely, the risk factors associated with this phenomenon are not known.

RESEARCH QUESTION: What factors are associated with an early undetectable [ASA] in salicylate poisoning?

METHODS: Records from a single regional poison center were searched from 2002 to 2016 for cases of salicylate toxicity treated with bicarbonate and [ASA] > 30 mg/dL. Cases were excluded if initial [ASA] was obtained >4 h after presentation. Case information, serial [ASA], and outcomes were recorded and compared between groups.

RESULTS: A total of 313 records met all criteria with 11 initially undetectable [ASA] (3.5%) and 302 detectable [ASA] (96.5%). Time of first [ASA] occurred sooner in the undetectable [ASA] group (89 vs. 137 min, p = 0.011) while time to peak [ASA] was longer (640 vs. 321 min, p < .001). The longest interval between ingestion and undetectable [ASA] was 225 min. Peak [ASA] and reported mean ingested dose were similar in both groups (45 vs. 50 mg/dL, p = NS; 19.7 g vs. 32.9 g, p = NS). Coingestion of agents that delay gastric emptying were similar in both groups (18% [2/11] vs. 25% [76/302], p = NS, chi-square). Hemodialysis was performed in 9% (1/11) of undetectable [ASA] patients and 5.6% (17/302) of detectable [ASA] patients (p = NS, chi-square). A single death occurred in the entire cohort in a patient with an initially detectable [ASA].

DISCUSSION: In this series, a small but significant proportion (3.5%) of patients who developed [ASA] > 30 mg/dL had an initially undetectable [ASA]. Those with an undetectable [ASA] were measured earlier after ingestion with a longer time to peak [ASA]. However, neither coingestion of agents prolonging gastric emptying nor reported dose ingested was different between groups. Formulation was infrequently recorded but one undetectable [ASA] did ingest a non-enteric coated product. Limitations include the small number of patients with undetectable [ASA], use of single poison center data and partial data on co-ingestants and aspirin formulation.

CONCLUSIONS: [ASA] may be undetectable early after an overdose and need for serial [ASA] in the evaluation of salicylate ingestion should be further explored. Additional research is needed to determine any causative factors and the optimal timing of [ASA] measurements.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Moss MJ, Fisher JA, Kenny TA, et al. Salicylate toxicity after undetectable serum salicylate concentration: a retrospective cohort study. Clin Toxicol (Phila). 2018. PMID: 30306804. doi:10.1080/15563650.2018.1502442

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。